Breath Therapeutics is developing liposomal formulations of cyclosporine A for inhalation to treat Bronchiolitis Obliterans Syndrome (BOS), a severe respiratory condition often seen in lung transplant patients. Their approach aims to improve drug delivery to the lungs, potentially enhancing treatment efficacy and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Bronchiolitis Obliterans Syndrome (BOS) is a severe respiratory condition, often affecting lung and stem cell transplant recipients, leading to significant morbidity and mortality. Effective treatments are lacking, and targeted drug delivery to the affected areas of the lung remains a challenge.
Solution
Zambon is developing liposomal formulations of cyclosporine A for inhalation (L-CsA-i) as a targeted therapy for Bronchiolitis Obliterans Syndrome (BOS). This inhaled formulation aims to improve the delivery of cyclosporine A directly to the lungs, potentially reducing systemic exposure and enhancing therapeutic efficacy. By encapsulating the drug in liposomes, Zambon seeks to optimize drug distribution within the lung and improve patient outcomes for this rare and severe respiratory disease. The L-CsA-i treatment is currently in Phase 3 clinical development.
Target Audience
The primary target audience includes patients diagnosed with Bronchiolitis Obliterans Syndrome (BOS), particularly those who have undergone lung or allogeneic hematopoietic stem cell transplants, and the healthcare professionals who treat them.
Features
- Liposomal encapsulation of cyclosporine A for enhanced drug delivery to the lungs.
- Inhalation-based administration for targeted treatment of BOS.
- Phase 3 clinical development program evaluating efficacy and safety.